Long‐term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Diabet. Med. 29, 1529–1533 (2012) Aims The goal of the study was to evaluate the efficacy of epalrestat, an aldose reductase inhibitor, on diabetic retinopathy and diabetic nephropathy, based on analysis of the results of the Aldose Reductase Inhibitor–Diabetes Complications Trial, a 3‐year multicentre comparative clinical trial of conventional therapy (control group) and epalrestat therapy (epalrestat group) in Japanese patients with mild diabetic neuropathy. Methods The subjects of the study were patients enrolled in the Aldose Reductase Inhibitor–Diabetes Complications Trial for whom data for major patient characteristics, severity of diabetic neuropathy at the end of the study and time‐courses of diabetic retinopathy and diabetic nephropathy were available (57 and 52 patients from the control and epalrestat groups, respectively). Progression of diabetic retinopathy/nephropathy (a primary endpoint) in relation to major patient characteristics, severity of diabetic neuropathy at the end of the study (assessed from the mean of z‐scores in four neurological function tests) and epalrestat treatment were analysed using univariate analysis and multiple logistic regression analysis. Results Progression of diabetic retinopathy/nephropathy was significantly inhibited in the epalrestat group compared with the control group (odds ratio = 0.323, P = 0.014) and was dependent on the severity of diabetic neuropathy at the end of the study (odds ratio = 2.131, P = 0.025). Conclusions Epalrestat prevented progression of diabetic neuropathy and retinopathy/nephropathy. The effect on diabetic retinopathy/nephropathy may have occurred indirectly because of the prevention of progression of diabetic neuropathy, in addition to the inhibitory action of epalrestat on aldose reductase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Self-citationStandards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Self-citationDyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Mechanism of diabetic neuropathy: Where are we now and where to go?
Yagihashi, S., Mizukami, H., & Sugimoto, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00070.x · Cited by 488
Cited by
Standards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 700
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
The aldo-keto reductases (AKRs): Overview
Penning, T. M. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.09.024 · Cited by 543
Metabolism of stromal and immune cells in health and disease
Ghesquière, B., Wong, B. W., Kuchnio, A., & Carmeliet, P. (2014) · Nature · doi:10.1038/nature13312 · Cited by 451
Dehdashtian, E., Mehrzadi, S., Yousefi, B., Hosseinzadeh, A., Reiter, R. J., Safa, M., Ghaznavi, H., & Naseripour, M. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.001 · Cited by 263
Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies
Rodríguez, M. L., Pérez, S., Mena-Mollá, S., Desco, M. C., & Ortega, Á. L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4940825 · Cited by 222
“Despite the polyol pathway having been related to DR, clinical trials using aldose reductase inhibitors have been inconclusive [78, 79] and show that further work is needed to understand the importance of the polyol pathway in DR development.”
MethodMechanistic Insights into Pathological Changes in the Diabetic Retina
Roy, S., Kern, T. S., Song, B., & Stuebe, C. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.08.022 · Cited by 206
Antioxidant Phytochemicals as Potential Therapy for Diabetic Complications
Akpoveso, O.-O. P., Ubah, E. E., & Obasanmi, G. (2023) · Antioxidants · doi:10.3390/antiox12010123 · Cited by 90
“The suppression of the polyol pathway has also been shown to impede the progression of experimental DPN, and clinical DPN, DN, and DR [88,89].”
BackgroundDecoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition
Liu, M., Qin, X., Li, J., Jiang, Y., Jiang, J., Guo, J., Xu, H., Wang, Y., Bi, H., & Wang, Z. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp05985e · Cited by 7
Metadata
- Authors
- Hotta, N., Kawamori, R., Fukuda, M., Shigeta, Y., & The Aldose Reductase Inhibitor–Diabetes Complications Trial Study Group
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2012-11-14
- Volume
- 29
- Issue
- 12
- Pages
- 1529-1533
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1576271256
- Cited by
- 135
- References
- 7
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.